

Medicines Update: February 2026

This medicines update is provided by the Veterinary Medicines Directorate (VMD) and lists new active substance, new marketing authorisations and changes to authorisations most relevant to vets.

New marketing authorisations

Novel products

- Mastavance 20 mg Intramammary Suspension is the first veterinary medicinal intramammary product to be authorised in GB containing only a corticosteroid (hydrocortisone aceponate). It is authorised for the treatment of the inflammatory signs of mild to moderate clinical mastitis in lactating cows.
- Intra Dysovinol 499 mg/ml Solution for Pigs contains a new active substance (Zinc disodium EDTA) in GB. It is authorised in drinking water for the treatment and metaphylaxis of dysentery due to *Brachyspira hyodysenteriae* infection in fattening pigs. The presence of the disease in the group must be established before the product is used.
- Numelvi Tablets for Dogs contain a new active substance (atinvicitinib) in GB. They are authorised for the treatment of pruritus associated with allergic dermatitis in dogs, and for the treatment of the clinical manifestations associated with atopic dermatitis in dogs, including pruritus. (The same products were authorised in NI in July 2025).
- Prevestrus Vet Film-coated Tablets for Dogs are the first veterinary medicinal products to be authorised in GB to contain finrozole. They are authorised to shorten the pro-oestrus and oestrus period, reduce clinical signs of heat, and reduce the risk of pregnancy, during a single oestrus cycle in the bitch. (The same products were authorised in NI in April 2025).

Table 1 shows the new marketing authorisations for February 2026

TABLE 1: New marketing authorisations in February 2026

New Marketing Authorisations			
Product name and target species	Active substance	Authorisation Holder, territory, and distribution category	Therapeutic group
Food Animals			
Biosuis ParvoEry Suspension for Injection for Pigs	Porcine parvovirus, Erysipelothrix rhusiopathiae	Bioveta, a.s. GB, POM-V	Inactivated Viral and Bacterial Vaccine
Carprofen Norbrook 50 mg/ml Solution for Injection for Cattle	Carprofen	Norbrook Laboratories Limited GB & NI POM-V	Anti Inflammatory NSAID

Intra Dysovinol 499 mg/ml Solution for Use in Drinking Water for Pigs	Zinc disodium EDTA, aqueous solution 39%	Intracare BV GB, POM-V	Gastrointestinal anti-diarrhoeal
Mastavance 20 mg Intramammary Suspension	Hydrocortisone aceponate	VIRBAC GB, POM-V	Anti Inflammatory corticosteroid
Vimectanin DUO 50 mg/ml + 1 mg/ml Oral Suspension for Sheep	Triclabendazole, Ivermectin	Pharma VIM Kft. GB, POM-VPS	Anthelmintic flukicide
Non-food Animals			
Iniram 10 mg/ml Solution for Injection for Dogs and Cats	Maropitant	Vet-Agro Multi-Trade Company Sp. z o.o. NI, POM-V	Gastrointestinal anti-emetic
Numelvi 4.8 mg / 7.2 mg / 21.6 mg / 31.6 mg Tablets for Dogs	Atinvicitinib	MSD Animal Health UK Limited GB, POM-V	Anti Inflammatory
Prevestrus Vet 25 mg / 50 mg / 100 mg Film-coated Tablets for Dogs	Finrozole	Vetcare Oy GB, POM-V	Anti Hormone Agent

See the VMD's [Product Information Database \(www.gov.uk/check-animal-medicine-licensed\)](http://www.gov.uk/check-animal-medicine-licensed) for more information on each of these products. There may be a delay before formal documentation is available for some Northern Ireland products, from the European Medicines Agency.

The timing of the product being placed on the market is an issue for the marketing authorisation holder.

Changes to authorisations most relevant to vets

The changes to authorisations most relevant to vets can be found below. Each product is listed, along with the authorisation holder, distribution category and details of which Summary of Product Characteristics (SPC) sections have been revised/changed.

Changes to the SPC, labels and leaflets may change how the medicines should be used. Details can be found on the VMD's Product Information Database (PID) at www.gov.uk/check-animal-medicine-licensed.

Due to ongoing assessments, there may be a delay between the point at which a new change is authorised and the updated SPC being available on the PID. There may also be a delay between the point at which any SPC changes are authorised and implementation in the product literature. Unless you have been advised otherwise, the labelling instructions on the pack which is dispensed should be followed.

Food producing animals

Dicla-cocci 2.5 mg/ml Oral Suspension for Cattle and Sheep

Huvepharma NV NI POM-VPS

Section 4: Addition of environmental properties: diclazuril has been shown to be very persistent in soil.

Emdoflaxin 50 mg/mL, Solution for Injection for Cattle, Pigs and Horses

Emdoka GB POM-V

Multiple sections of the SPC have been significantly revised including 3.2 Indications, 3.3 Contraindications, 3.5 Special precautions for use, 3.6 Adverse events, 3.7 Use during pregnancy, lactation, or lay, 3.8 Interactions, 3.9 Administration routes and dosage, 3.10 Overdosage, and 3.12 Withdrawal periods.

Florgane 300 mg/ml Suspension for Injection for Cattle and Pigs

Emdoka bvba GB & NI POM-V

Section 3.2: Indication for use in cattle updated from 'preventative' to 'metaphylactic': The presence of the disease in the herd should be established before metaphylactic treatment.

Flunixin 50 mg/ml Solution for Injection for Cattle, Horses and Pigs

Norbrook Laboratories Limited GB & NI POM-V

Multiple sections of the SPC have been significantly revised including 3.2 Indications, 3.3 Contraindications, 3.5 Special precautions for use, 3.6 Adverse events, 3.7 Use during pregnancy, lactation, or lay, 3.8 Interactions, 3.9 Administration routes and dosage, 3.10 Overdosage, and 3.12 Withdrawal periods.

Hipnoton 10 mg/ml Solution for Injection for Horses and Cattle

Vetpharma Animal Health, S.L GB & NI POM-V

Multiple sections of the SPC have been revised including Section 3.6: Additional adverse events in cattle of penile prolapse (transient) at a frequency of very common, uterine contraction, nasal discharge, hyperthermia, and hypothermia at a frequency of common, arrhythmia at a frequency of rare, and heart block at a frequency of very rare. Additional adverse events in horses of uterine contraction, hyperthermia, and hypothermia at a frequency of very common, hypersalivation, nasal discharge and skin swelling at a frequency of common, and hypersensitivity reaction at a frequency of very rare.

Section 3.9: Addition of dosage instructions for combinations with other active substances.

Norfenicol 300 mg/ml Solution for Injection for Cattle and Pigs

Norbrook Laboratories Limited NI POM-V

Section 4.5: Other precautions updated with risks for plants and water organisms.
Section 6.6: Special precautions for the disposal of the product updated: The veterinary medicinal product should not enter water courses as florfenicol may be dangerous for fish and other aquatic organisms.

Somnipron 10 mg/ml Solution for Injection for Horses and Cattle

Vetpharma Animal Health, S.L GB & NI POM-V

Multiple sections of the SPC have been revised including Section 3.6: Additional adverse events in cattle of penile prolapse (transient) at a frequency of very common, uterine contraction, nasal discharge, hyperthermia, and hypothermia at a frequency of common, arrhythmia at a frequency of rare, and heart block at a frequency of very rare.

Additional adverse events in horses of uterine contraction, hyperthermia, and hypothermia at a frequency of very common, hypersalivation, nasal discharge and skin swelling at a frequency of common, and hypersensitivity reaction at a frequency of very rare.

Section 3.9: Addition of dosage instructions for combinations with other active substances.

Companion animals

Caninsulin 40 IU/ml Suspension for Injection (Cats, Dogs)

Intervet International B.V. UK POM-V

Section 3.3: Do not use in cases of hypoglycaemia.

Section 3.6: Addition of adverse event; hypoglycaemia at a frequency of 'Rare' (more than 1 but less than 10 animals in 10,000 animals treated).

Easimax Plus Tablets for Dogs

Chanelle Pharmaceuticals Manufacturing Ltd NI NFA-VPS

Section 4.6: Addition of adverse events; lethargy, anorexia, and hyperactivity at a frequency of very rare (<1 animal / 10,000 animals treated, including isolated reports).

Lotimil 12 mg / 48 mg Chewable Tablets for Cats

Elanco Europe Ltd GB POM-V

Section 3.6: Addition of adverse events; anorexia, lethargy, tachypnoea, ataxia, muscle tremor, hyperactivity and pruritus at a frequency of very rare (<1 animal / 10,000 animals treated, including isolated reports).

Melosus 0.5 mg/ml Oral Suspension for Cats and Guinea Pigs

CP Pharma Handelsgesellschaft mbH GB POM-V

Section 4.2: New indication of alleviation of pain and inflammation in acute musculo-skeletal disorders in cats. Corresponding additional dosage instructions in Section 4.9.

Nexgard Spectra Chewable Tablets for Dogs [Range]

Boehringer Ingelheim Vetmedica GmbH GB POM-V

Section 3.2 Addition of two new indications:

For reduction of the risk of infection with *Babesia canis* via transmission by *Dermacentor reticulatus* for 28 days.

For reduction of the risk of infection with *Dipylidium caninum* via transmission by *Ctenocephalides felis* for 30 days.

The effects are indirect due to the activity of the veterinary medicinal product against the vector.

Nobivac Rabies (Cats, Dogs)

Intervet International B.V. UK POM-V

Section 3.6: Addition of adverse events; lethargy, anorexia and hyperthermia at a frequency of very rare (<1 animal/ 10,000 animals treated, including isolated reports).

Section 3.8: Addition of a claim for an associated non-mixed use with Nobivac L4

Propofol-Lipuro Vet 10 mg/ml Emulsion for Injection (Cats, Dogs)

B. Braun Melsungen AG UK POM-V

Section 3.6: Addition of adverse events; paddling, myoclonus, opisthotonus at a frequency of common (more than 1 but less than 10 animals in 100 animals treated).

Quantilex Plus XL Tablets for Dogs

Chanelle Pharmaceuticals Manufacturing Ltd NI NFA-VPS

Section 3.6: Addition of adverse events; lethargy, anorexia, and hyperactivity at a frequency of very rare (<1 animal / 10,000 animals treated, including isolated reports).

YURVAC RHD Emulsion for Injection for Rabbits

Laboratorios Hipra SA GB POM-V

Section 3.6: Addition of adverse events; lethargy, and lameness at a frequency of very rare (<1 animal/10,000 treated, including isolated reports).

For more information, contact the VMD at postmaster@vmd.gov.uk